Pluronic

PreclinicalSmall molecule

UUniversity of Virginia

Pluronic is one of 6 small molecule programs targeting Colonization. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColonizationCompleted

ColonizationPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Colonization

#DrugCompanyPhaseTrials

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Approved

1 2

Allogenic FMT

UUniversity Hospital, Ghent

Phase 3

1 3

Bactroban

PPadagis LLC

Preclinical

4 4

Donor FMT

FFondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2

2 5

Xylitol

JJoseph Zabner

Phase 1

1 6

Pluronic

UUniversity of Virginia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colonization2 trials

Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections

Completed·UUniversity of Virginia·N/A·NCT01886001·53 enrolled

Umbilical Cord Care for the Prevention of Colonization

Unknown status·UUniversity of Virginia·N/A·NCT01893060·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pluronic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pluronic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pluronic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Virginia

Pluronic

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colonization2 trials

References

Drug Info

Quick Facts

Related News